Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.57 |
| ▸ | CES1 | P23141 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14415722 | 0.87 | CES2 (0.59) | CES2CES1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3038873 | 0.86 | CES2 (0.63) | CES2CES1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL809735 | 0.86 | ATM (0.67) | CES2CES1ALDH1A1TSHRSRD5A2 | |
| SCHEMBL1258944 | 0.86 | CES2 (0.74) | CES2CES1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29623677 | 0.84 | ATM (0.71) | CES2CES1NPC1RAB9AALDH1A1 | |
| SCHEMBL3834026 | 0.84 | ATM (0.71) | CES2CES1NPC1RAB9AALDH1A1 | |
| SCHEMBL2705684 | 0.84 | CES2 (0.71) | CES2CES1SMN1; SMN2PARP1TDP1 | |
| Hydrochloric Acid SCHEMBL27733562 | 0.84 | CES2 (0.71) | CES2CES1SMN1; SMN2PARP1TDP1 | |
| SCHEMBL2788774 | 0.83 | CES2 (0.59) | CES2CES1NPC1RAB9ASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL27493894 | 0.82 | ATM (0.68) | CES2CES1NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117301405-A | Processing technology of high-transparency resin | 镇江利德尔复合材料有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-117208895-A | Preparation method of easily-dispersed high-conductivity carbon nanotubes | 苏州信敏惠纳米科技有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-103626991-B | A kind of high workability polyethersulfone ketone resin and industrialized producing technology thereof | JIANGMEN YOUJU NEW MATERIALS Co.,Ltd. (CN) | 2016-02-24 | — | — | CN | claimed |
| CN-103642031-B | A kind of high-flow polyphenylene ether sulfone ketone resin and industrialized producing technology thereof | JIANGMEN YOUJU NEW MATERIALS Co.,Ltd. (CN) | 2015-09-09 | — | — | CN | claimed |
| CN-103642029-B | A kind of high workability polyethersulfone ketone resin and Industrialized synthesis method thereof | JIANGMEN YOUJU NEW MATERIALS Co.,Ltd. (CN) | 2015-07-29 | — | — | CN | claimed |
| CN-117301405-A | Processing technology of high-transparency resin | 镇江利德尔复合材料有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117208895-A | Preparation method of easily-dispersed high-conductivity carbon nanotubes | 苏州信敏惠纳米科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-3233799-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10752588-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190345105-A9 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20190023656-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| EP-3233799-A1 | DOPAMINE D2 RECEPTOR LIGANDS | The Broad Institute Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-1630187-B1 | Sulfonic group-containing polyarylene block copolymer, process for production thereof, solid polymer electrolyte and proton conductive membrane | JSR CORP (JP) | 2008-05-21 | — | — | EP | disclosed |
| US-7368068-B2 | Sulfonic group-containing polyarylene block copolymer, process for production thereof, solid polymer electrolyte and proton conductive membrane | JSR CORPORATION (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20060280991-A1 | Membrane-electrode assembly for solid polymer electrolyte fuel cell | HONDA MOTOR CO., LTD. | 2006-12-14 | — | — | US | disclosed |
| US-20060043344-A1 | Sulfonic group-containing polyarylene block copolymer, process for production thereof, solid polymer electrolyte and proton conductive membrane | JSR CORPORATION (JP) | 2006-03-02 | — | — | US | disclosed |
| EP-1630187-A1 | Sulfonic group-containing polyarylene block copolymer, process for production thereof, solid polymer electrolyte and proton conductive membrane | JSR Corporation (JP) | 2006-03-01 | — | — | EP | disclosed |
| US-20050014788-A1 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| EP-1448524-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003042177-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY (ESPECIALLY CCR5) | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014788-A1 | Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) | CCR5, CCR2, CCL2 | CES2 824/4885CES1 1523/4885NPC1 946/4885 |
| US-20190345105-A9 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | CES2 526/4885CES1 3591/4885NPC1 2458/4885 |
| US-20190023656-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | CES2 526/4885CES1 3591/4885NPC1 2458/4885 |
| US-10752588-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | CES2 526/4885CES1 3591/4885NPC1 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.